Psilocybin acts as a partial agonist at the 5-HT2A serotonin receptor. In this simulation, the violet particles represent psilocin (the active metabolite) binding to these receptors.
This binding triggers a neuroplasticity cascade, potentially increasing Brain-Derived Neurotrophic Factor (BDNF) and promoting rapid, albeit transient, synaptic sprouting and network reconnection, bypassing some amyloid obstructions.
Limitations & Context
Single Case Study: This simulation is based on a single documented case report from Frontiers, not a large-scale clinical trial.
Transient Effect: The functional recovery observed was temporary. As the substance clears, the network typically returns to its baseline degenerated state.
Not a Cure: This illustrates a potential "reset" or temporary bypass mechanism, not a reversal of the underlying Alzheimer's pathology (amyloid plaques/tau tangles).